TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nordic Orofacial Test-Screening (NOT-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day-28 mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in serial HbA1C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention or amelioration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Nail Length of Hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Nail Length of Digits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure at 30 Days of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail Brittleness at 30 Days of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Intolerable Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Neutrophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Neutrophils in Induced Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time for the concentration of GT103 to reach half of the level administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D) of GT103
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suitable for discharge
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: PF-06650833 Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF-06650833 AUCtau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF-06651600 Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF-06651600 AUCtau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol goal attainment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average thrombolysis in myocardial infarction (TIMI) frame count (TFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Multiple Sclerosis Inventory Cognition (MUSIC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Annual Corpus Callosum Index decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom From Major Adverse Events (MAEs) at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Average length of stay in secondary care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Extent of tissue damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of tissue damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events evaluated with NCI-CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Non-accidental mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of attempts needed to achieve deep cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone Acetate (MPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Cmax (Tmax) of MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Drug Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Yale Global Tic Severity Scale Tic Severity Score (YGTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in regional brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain evaluation using the verbal analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' beliefs involving tobacco product use - pre test survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' beliefs involving tobacco product use - post test survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' knowledge involving tobacco product use - pre test survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants' knowledge involving tobacco product use - post test survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: KOOS pain subscale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Incidence of postoperative neurocognitive disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Survival embryo rate
Endpoint domain: Mortality/survival
Primary endpoint: Bilateral Muscle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adherence to HIV medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased HB antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood Bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Achieving Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ceftazidime concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events or Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Functional use of hand and comfort while wearing orthotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage compliance with prescribed wearing schedules
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage compliance with HEP performance schedule
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number and proportion of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and proportion of participants experiencing abnormal clinically relevant hematology or clinical chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Zonulin concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral absolute rSO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long Term CHANGE in Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: doxorubicin pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of painful symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AE
Endpoint domain: Adverse events/effects
Primary endpoint: ECG test evaluated by QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of adverse events during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events during follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Pregnancy Success Rate
Endpoint domain: Mortality/survival
Primary endpoint: Healthcare utilization exacerbation rate per year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of amyloidosis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Complete Ductoscopic Retrievals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of RSV-associated LRI or apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in learning assessed by fast-mapping task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Organelle Biogenesis (Mitochondrial) Acute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaerobic Exercise Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organelle Biogenesis (Mitochondrial) Chronic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean monofilament value for sensory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication of rhinovirus from nasal secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to next respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of mean carotid vessel wall fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of patients retained in study protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Provider satisfaction assessed by Treatment Evaluation Inventory-Short Form (TEI-SF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adolescent satisfaction assessed by the Client Satisfaction Questionnaire (CSQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Engagement assessed by the Child Improvement Rating Scale (CIRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Highest tolerable dose of BMTP-11
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Correlation of results with Outcome
Endpoint domain: General outcomes
Primary endpoint: Classification of sputum eosinophilic and non-eosinophilic asthmatics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of disease detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor SUVmax value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell-free DNA (AlloSure) levels after maximal cardiopulmonary exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke ejection volume (SEV) measure by ClearSight®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke ejection volume measure by PICCO®
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: days per week with fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dynamic Balance in the Four Square Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal pressure-flow-relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of best practice alerts accepted or rejected
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Annualized number of injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Status of nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Electrogram characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Ambulating Early After Spinal Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of SARS-CoV-2 contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-digestion flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gluteus muscle torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Free Survival at 5 Years
Endpoint domain: Mortality/survival
Primary endpoint: Objective response rate (PR and CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mortality at 14 days
Endpoint domain: Mortality/survival
Primary endpoint: Peel force used to remove adhesive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of the restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent caries during examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation of the restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective feeling of physical comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Function of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Observed Treatment Lines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Patients Per Most Frequently Prescribed Non-COPD Agents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Loosening Rates of the Glenoid and Humeral Components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: qEEG parameter IS correlation with POCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Change Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: microRNA levels in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of patients with known and novel antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Autism Diagnostic Interview Revised (ADI-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic properties of Shear wave Elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B Envelope Antigen (HBeAg) Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBsAg Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to AV Fistula Functional Maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 2h postprandial blood glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of breakthrough pain episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of self-administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of abnormal cerebral protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of primary efficacy failure
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in maximal voluntary contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in intestinal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of biomarkers for predicting prostate cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Amount of drink consumed (alcohol or placebo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA levels of NRF2 and NRF2-dependent phase II enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in the Young Mania Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Chronic Exertional Compartment Syndrome (CECS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Initial Survey Responses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PET Activity Estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-Term Care Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost Measures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of Postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endogenous response of incretins, orexins and anorexins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Evening Pain Intensity in the Target Knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DNA damage response to PARP inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of brain amyloid deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activation of p53
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of food preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change in self-efficacy using a 16 items scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COVID-19 Symptom Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With New Adverse Event (AE) ≥ Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD Scores on the PCL-M Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant's awareness of sexual health issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for sexual health intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of episodes of nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic yield of pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Positive Atopy Patch Testing Reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: hospitalization rates for hemorrhage or thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Self monitored BG (SMBG) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body weight/body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Pediatric Assessment of Emergence Delirium (PAED) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Overall Survival - Percentage of Participants With an Event
Endpoint domain: Mortality/survival
Primary endpoint: Duration of Overall Survival - Time to Event
Endpoint domain: Mortality/survival
Primary endpoint: Immediate particulate clearance capacity of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Prespecified Local Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Prespecified Systemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of histopathology analyses and interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of modified Rankin Scale grades
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: anatomo-functional reorganization profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diaphragmatic thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in salivary secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes